Study on Cialis (Eli Lilly) in men with Erectile Dysfunction published in Journal of Sexual Medicine

Study results published in the Journal of Sexual Medicine showed a greater percentage of men with Erectile Dysfunction who had an incomplete response to as-needed PDE5 inhibitor treatment returned to normal erectile function when given Cialis (tadalafil), from Eli Lilly, compared to placebo, as measured by the erectile function domain of the International Index of Erectile Function (IIEF-EF). The randomized, double-blind, parallel, placebo-controlled trial enrolled 623 subjects who were randomly assigned to receive treatment with Cialis for once daily use or placebo.

In a pre-specified secondary measure, Cialis significantly improved erectile function scores versus placebo in those men who had an incomplete response to as-needed PDE5 treatment. The most common treatment-emergent adverse events observed in the study were consistent with other Cialis studies and included headache, back pain and upset stomach.